Taken together, these data demonstrate that circ-EGFR enhances cetuximab sensitivity in CRC cells, suggesting that circ-EGFR may be a potential predictor of cetuximab response in metastatic colorectal cancer (mCRC). Here, EGFR is linked to colorectal carcinoma.